Non-steroidal anti-inflammatory drugs (NSAIDs), statins, glucocorticoids and monoclonal antibodies (e.g., targeting IL-6, TNF-, IL-12/23) have been reported to show moderate anti-depressant capacity in patients with somatic disorders (i.e., rheumatoid arthritis, psoriasis) who also had comorbid symptoms of depression [194, 195]
Laboratory findings in the form of low hemoglobin or hematocrit should be recorded in clinical documentation
Unlike most signalling peptides in the research literature, BPC-157 does not target a single well-characterised receptor
aeruginosa showed resistance (127)
The real breakthrough occurred when researchers paired NAD+ therapy with a powerful compound that your body cant produce on its own, called 5-Amino-1MQ